Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care

Urol Clin North Am. 2021 Aug;48(3):311-322. doi: 10.1016/j.ucl.2021.03.003. Epub 2021 Jun 12.ABSTRACTGermline testing for prostate cancer (PCA) is revolutionizing PCA care. Two PARP inhibitors are FDA approved for men with metastatic, castration-resistant disease after progression on first-line therapies. In the screening setting, genetic test results may inform initiation and screening strategies. For men with early-stage disease, literature is emerging on the possible role of germline testing in active surveillance discussions. As such, urologists and oncologists must gain working knowledge of the principles and practice of germline testing and hereditary cancer implications for responsible implementation. Here the authors outline key learning areas and practice strategies for responsible dissemination of PCA germline testing.PMID:34210487 | DOI:10.1016/j.ucl.2021.03.003

Source: The Urologic Clinics of North America - July 2, 2021 Category: Urology & Nephrology Authors: James Ryan Mark Carey McDougall Veda N Giri Source Type: research